AVBP
NASDAQ
$28.22
ArriVent BioPharma Inc (AVBP)
ArriVent BioPharma, Inc. (AVBP) is an innovative biopharmaceutical company committed to advancing groundbreaking therapies for critical unmet needs in oncology and autoimmune diseases. Leveraging proprietary technologies and a robust scientific foundation, ArriVent is focused on delivering improved patient outcomes through its promising pipeline. With strategic positioning in high-growth sectors of the biopharma industry, the company represents an attractive investment opportunity for institutional investors seeking to capitalize on transformative healthcare advancements with the potential for significant market impact.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $43.64 (+54.64%)
Market Cap
$1.49B
Free Cash Flow Yield
-9.01%
Beta (5Y)
0.94
Price Chart
Valuation
Market Cap$1.49B
P/B4.68
Profitability
Total Revenue (TTM)$12M
EBITDA-$145M
EPS-$3.49
Financial Health
Free Cash Flow Yield-9.01%
Growth & Risk
Beta (5Y)0.94
Sharpe Ratio0.60